A recent report suggests that global incidence of Mycobacterium avium infections is significant and underestimated [1]. In immune-compromised hosts, for instance, patients infected with HIV, M. avium can cause chronic-disseminated disease with significant morbidity and mortality [2] . M. avium infections are difficult to treat as this pathogen is naturally resistant to most antibacterials available today. Therefore, new insights into vulnerabilities of this pathogen, that may be exploited to develop effective therapies, can have an immediate and a lasting impact.
A recent report suggests that global incidence of Mycobacterium avium infections is significant and underestimated [1] . In immune-compromised hosts, for instance, patients infected with HIV, M. avium can cause chronic-disseminated disease with significant morbidity and mortality [2] . M. avium infections are difficult to treat as this pathogen is naturally resistant to most antibacterials available today. Therefore, new insights into vulnerabilities of this pathogen, that may be exploited to develop effective therapies, can have an immediate and a lasting impact.
Mycobacteria possess a large cell wall that accounts for approximately 40% of cell's dry mass [3] . As a major component of the cell wall, the peptidoglycan serves as an anchor to vital cell wall molecules via covalent linkage to arabinogalactan layer to which mycolic acids are associated [4] . Until recently, it was widely accepted that D,D-transpeptidases (commonly known as penicillin-binding proteins) catalyzed the final step of peptidoglycan biosynthesis by linking the fourth amino acid of one stem peptide to the third amino acid of another thereby generating a 4→3 linked 3D-exoskeleton. However, the peptidoglycan of Mycobacterium tuberculosis, Mycobacterium abscessus and Mycobacterium smegmatis are predominantly cross-linked with 3→3 linkages generated by non-classical transpeptidases, namely L,D-transpeptidases [5] [6] [7] [8] [9] . Unlike D,D-transpeptidases that use serine to catalyze transpeptidation reaction, the catalytic residue in L,D-transpeptidases is cysteine which when mutated to serine completely abrogates its RESEaRch aRticlE Mattoo, Lloyd, Kaushik et al. future science group activity [10] . The predominance of 3→3 crosslinked peptidoglycan in M. tuberculosis is an important reason why β-lactam sub-classes, penicillins and cephalo sporins are ineffective against this pathogen [6, 11] . Penicillins and cephalosporins are also not considered for treatment of M. avium infection as their minimum inhibitory concentration (MIC 90 ) against this pathogen are approximately 40-160 μg/ml [12] and therefore therapeutically irrelevant. In addition to the native β-lactamase present in M. avium [13] , the presence of L,D-transpeptidases could potentially contribute toward natural resistance to penicillins and cephalosporins as this class of β-lactams are not known to be effective against L,D-transpeptidases [10, 11] . An M. tuberculosis strain lacking the dominant L,D-transpeptidase, Ldt Mt2 , manifested altered cell and colony morphologies, loss of virulence and enhanced sensitivity to β-lactams [6, 14] . Here, we began with genomic approaches to identify Ldt Mt2 orthologs of M. tuberculosis L,D-transpeptidases in M. avium, and focused on an ortholog of Ldt Mt2 , hereafter referred to as Ldt Mav2 . We used biochemical, biophysical, genetic and microbiological approaches to characterize this protein. We explored localization, abundance and relevance of Ldt Mav2 to physiologically relevant stresses and characterized its interactions with β-lactams. Although generally not considered for treatment of M. avium infections, data from our study merit further investigation of the therapeutic utility of carbapenems against this pathogen. In particular, our finding that a new carbapenem that is orally bioavailable, namely tebipenem, has potent in vitro activity can have direct impact on the treatment of M. avium infections that are resistant to existing drugs.
Materials & methods

•
• Bacterial strains & growth conditions M. avium 104, a clinical isolate [15] , was used in this study and was grown in Middlebrook 7H9 broth (Becton and Dickinson, Sparks, MD, USA) supplemented with 10% (v/v) oleic acid/albumin/dextrose/catalase (OADC), 0.2% glycerol, 0.05% Tween-80 and 50 μg/ml cycloheximide (7H9 complete medium) at 37°C with constant shaking. To assess response to stress, M. avium was grown in 7H9 complete medium to exponential phase (A 600 nm = 0.6), centrifuged, washed once with 7H9 broth and resuspended in 7H9 complete medium alone (control), H 2 O or 7H9 medium supplemented with the following: 0.05% sodium dodecyl sulfate (SDS) or 2 μg/ml crystal violet or 1 μg/ml tebipenem. M. avium was also incubated in Sauton's medium alone and Sauton's medium supplemented with 40 μM ferric ammonium sulfate. Escherichia coli strains, DH5α and BL21(DE3), were grown in LuriaBertani (LB) broth or LB agar with appropriate selection drug.
•
• Sequence analysis of Ldt Mav2
Sequence of Ldt Mav2 was obtained from the Kyoto Encyclopedia of Genes and Genomes (KEGG) M. avium 104 database [16] . Sequence alignment to compare primary structure of Ldt Mav2 with its orthologs in other mycobacteria and to infer residues potentially involved in catalysis was undertaken using Multiple Alignment using Fast Fourier Transform (MAFFT) [17] . Furthermore, Clustal X was used to color classify each amino acid. The cladogram construction of the sequences was carried out using MEGA 6.06 [18] .
• Cloning, overexpression & purification
The N-terminal 24 residues of Ldt Mav2 were excluded to avoid the likely transmembrane anchor predicted by TMHMM [19] that could hinder purification of the protein. Primers attgccatatggtgggggcagtcgcctgcggcg and caatactcgagtcaggtgttggcgttgcccgc were used to amplify the region-encoding residues 25-403 and cloned into pET28a+TEV to generate an N-terminal H 6 tagged Ldt Mav2 . E. coli BL21δε3 was used to overexpress Ldt Mav2 , treated with TEV protease to cleave the H 6 tag while simultaneously dialyzed to remove imidazole. Gel filtration was carried out using Superdex-200 10/300 GL (GE Healthcare, IL, USA) to obtain monomeric Ldt Mav2 .
• Biochemical characterization
The optimum pH for Ldt Mav2 was determined by assessing absorbance of opening of the β-lactam ring of nitrocefin at 490 nm, molar extinction coefficient of 20,500 M -1 cm -1 as described [20] . Reaction mixtures contained 10 μM Ldt Mav2 , 100 μM nitrocefin, 100 mM-modified buffer containing 2-(N-Morpholino)ethanesulfonic acid (MES), 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) and diethanolamine (1:1:1) at pH ranging from 4 to 10 [21] future science group www.futuremedicine.com and 0.1 mM TCEP at 25°C in a total volume of 100 μl. To study Ldt Mav2 reaction kinetics, nitrocefin was used as a substrate at varying concentrations at 25°C. For each reaction, a control in which the rate of nitrocefin hydrolysis in the absence of enzyme at each pH and substrate concentration was included. The K m and V max were determined using nonlinear regression analysis of which Michaelis Menton gave the best fit using Graph pad prism (Version 6; La Jolla, CA, USA). To characterize reaction between Ldt Mav2 and various β-lactam subclasses, enzyme-inhibitor (EI) complex was prepared by incubating Ldt Mav2 with 200 μM of carbapenem at 25°C for 2 h. Unreacted inhibitor was removed by size exclusion chromatography. The purified acyl-enzyme was incubated with nitrocefin and its hydrolysis was monitored at 495 nM. Nitrocefin incubated with unreacted Ldt Mav2 was included as a control. To identify adduct formed with Ldt Mav2 , each β-lactam was incubated at 4 mM concentration with 2 μM enzyme in 400 μl of 25 mM Tris, pH 8, for 5 h at room temperature. These samples were analyzed using a Waters Aquity H-Class Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS) system and adducts were identified as previously described [10] .
• Determination of kinetic rate constants
The λ max for each β-lactam was determined spectroscopically and they are: amoxicillin, 272 nm; cephalothin, 270 nm; doripenem, 300 nm; faropenem, 306 nm; and T210, 303.5 nm. T210 is an experimental carbapenem synthesized by our group [10] . Extinction coefficients for these compounds were determined for doripenem (7500 M ) and T210 (9880 M -1 cm -1 ). A stopped-flow apparatus (SX20; Applied Biophysics, NY, USA) was used to measure fluorescence of reaction in sodium phosphate buffer, pH 7.4 at 10°C as described [22] . Fluorescence emission was recorded at 320 nm. Fluorescence data were analyzed using regression analysis using the equation [ Abundance of Ldt Mav2 was studied using western blot analysis with polyclonal antibody generated against full-length Ldt Mav2 in rabbits (Spring Valley Laboratory, MD, USA). M. avium cultures grown to exponential (A 600 nm = 0.6) and stationary phases of growth (A 600 nm ∼2.4) were used to extract cytosolic and membrane protein fractions, electrophoresed on 10% SDS-PAGE gels and transferred to a polyvinylidene difluoride membrane (GE Healthcare, IL, USA). Following overnight blocking, the membrane was incubated with anti-Ldt Mav2 polyclonal antibody (1:1000) in Tris-buffered saline (TBS) containing 0.2% bovine serum albumin (BSA) and 0.1% Tween-80 (TBS-T) for 2 h at room temperature and was washed three-times with TBS-T for 15 min and incubated with secondary antirabbit-horseradish peroxidase conjugate (Cell Signaling, MA, USA). The blot was washed three-times with TBS-T, and developed using chemiluminescence. Purified Ldt Mav2 was included as a control.
Cellular localization of Ldt Mav2 was studied using cell wall and cytosolic fractions of M. avium prepared from exponential and stationary-phase cultures using a slight modification of a validated protocol [23] . Expression levels of Ldt Mav2 in M. avium was assessed from whole-cell lysates made using M. avium 104 cultures grown to exponential (A 600 nm = 0.6) and stationary phase (A 600 nm = 2.4). The cells were centrifuged at 3000 ×g for 10 min at 4°C, the pellet was resuspended in a buffer containing 50 mM TrisHCl (pH 8), 150 mM NaCl, 0.1 mM TCEP, 1 mM PMSF, 10% glycerol and treated with lysozyme (2 mg/ml overnight at 4°C). This sample was sonicated on an ice-ethanol mixture followed by centrifugation at 3000 ×g for 10 min to remove any unbroken cellular debris. The lysate obtained after sonication was centrifuged at 3000 ×g for 10 min to remove cellular debris and then centrifuged again at 30,000 ×g for 30 min at 4°C. The supernatant from this sample represents the cytosol and cell pellet is the cell wall fraction. The cell RESEaRch aRticlE Mattoo, Lloyd, Kaushik et al. future science group lysate proteins after quantification using the modified Bradford method [24] and normalization were electrophoresed on 10% SDS-PAGE gels and transferred to a polyvinylidene difluoride membrane (GE) using a semidry transfer apparatus (Bio-Rad, Hercules, CA, USA). The membrane was blocked using 5% blocking solution nonfat dry milk (Cell Signalling, MA, USA) in the presence of a buffer containing 0.2% BSA in TBS (20 mM Tris-HCl [pH 7.4], with 150 mM NaCl) overnight. Excess blocking agent was removed by washes in a buffer containing TBS (20 mM Tris-HCl [pH 7.4], with 150 mM NaCl) and 0.1% Tween-20. The membrane was then incubated with the polyclonal anti-Ldt Mav2 antibody (1:1000) in TBS containing 0.2% BSA and 0.1% Tween-80 for 2 h. The membrane was washed threetimes with TBS containing 0.05% Tween-20 over 15 min and incubated with secondary antirabbit-horseradish peroxidase conjugate (Cell signaling) at a 1:10,000 dilution for 1 h. The blot was washed three-times with TBS-T, and was developed using chemiluminescencedeveloping kit (Santa Cruz Biotechnology, TX, USA), following the manufacturer's protocol. Purified MAV_1661 was used as a control.
• Protein-protein interaction
A pull-down assay was used to identify any protein(s) that interacted with Ldt Mav2 . M. avium lysate was prepared as described above from cultures harvested at exponential growth phase (A 600 nm = 0.6). The lysate was first interacted with Ni-NTA resin at 4°C for 2 h. This precleared lysate was interacted with His-tagged Ldt Mav2 immobilized on Ni-NTA agarose resin at 4°C for 2 h. The beads were washed with 0.5% Triton-X, 50 mM Tris-HCl (pH 8), 150 mM NaCl, 0.1 mM TCEP, 1 mM PMSF, 10% glycerol and 5 mM imidazole and analyzed using 10% SDS-PAGE gel. The protein band that was exclusively present in the presence of Ldt Mav2 was excised, digested with trypsin and subjected to mass spectrometric analysis to determine the peptide fragment masses, which were then, analyzed against the MASCOT database to identity the protein.
• • Minimum inhibitory concentration & checkerboard titration assay MIC 90 of agents against M. avium was determined using the standard broth microdilution assay [25] , using 96-well plates separately at pH 6.8 (Middlebrook 7H9 broth in the presence of 10% OADC) and pH 7.4 (cationadjusted Mueller-Hinton broth) in accord with the Clinical and Laboratory Standard Institute (CLSI) [26] guidelines described in [27] . Standard Checkerboard Titration assay [28] was used to assess combined activity of agents. Two drugs were added to 2.5 ml of Middlebrook 7H9 broth, each starting at its MIC 90 and serially diluted twofold, so all possible twofold dilution combinations below respective MICs are represented. Next, 10 5 CFU of M. avium were inoculated into each tube. The cultures were incubated at 37°C and evaluated for growth by visual inspection of the broth at 9 days as per CLSI guidelines. Fractional inhibitory concentration (FIC) of a drug was calculated as described [28] . FIC of a drug in a sample is computed as concentration of the drug divided by the MIC of the drug when used alone. FIC index is the sum of FIC of two drugs in a sample. FIC index was calculated for each mix of drugs that inhibited M. avium growth and an average FIC index was determined. Average FIC index ≤0.5 was interpreted as synergy, 0.5-2.0 as indifference and more than two as antagonism.
Results
•
• Ldt Mav2 is conserved across most mycobacteria
We u s e d L dt Mt 2 , t he d om i n a nt L,D-transpeptidase in M. tuberculosis [6] , to identify its sequence ortholog, Ldt Mav2 , in M. avium 104. According to the existing annotation (accession WP_033706218.1), Ldt Mav2 is a 379 aa protein encoded by locus MAV_1661 [29] . Ldt Mav2 shares 86% sequence identity with Ldt Mt2 and possesses a C-terminal YkuD domain (Pfam 03734) that is characteristic of L,D-transpeptidases and two bacterial immunoglobulin-like domains (Ig) in the N-terminus (Supplementary Figure 1) [30] . M. tuberculosis [5, 7] and M. abscessus [8] concentrations of cell wall perturbants such as sodium dodecyl sulfate [31] , crystal violet [32] and the peptidoglycan biosynthesis inhibitor tebipenem [33] . While Ldt Mav2 levels were similar in M. avium grown in the nutrientrich Middlebrook 7H9 complete medium and Sauton's broth supplemented with 100 μM iron, a small but noticeable decrease was observed in the presence of 40 μM iron, 0.05% sodium dodecyl sulfate and 2 μg/ml crystal violet ( Figure 1C ). Exposure to 1 μg/ml tebipenem and osmotic shock resulted in very low levels of Ldt Mav2 .
• Ldt Mav2 hydrolyzes β-lactam substrate
H6-tagged Ldt Mav2 (25-403 aa fragment) was expressed in the heterologous host E. coli BL21δε3, and purified to apparent homogeneity using Ni-NTA chromatography. Further purification and assessment by gel filtration revealed that Ldt Mav2 is stably present in its monomeric form. Attempts to purify the YkuD domain alone (residues 253-403) were unsuccessful (data not shown), suggesting that perhaps the Ig domains are essential for stabilizing the YkuD fold. L,D-transpeptidases bind to and hydrolyze a tetrapeptide substrate during peptidoglycan biosynthesis [11] . By mimicking the native substrate, β-lactams are also bound and hydrolyzed by L,D-transpeptidases Ldt Mt1 [34] , Ldt Mt2 [30] and Ldt Mt5 of M. tuberculosis [20] . Given extensive sequence similarity to Ldt Mt2 , we hypothesized that Ldt Mav2 would also bind to and catalyze hydrolysis of β-lactams. We used nitrocefin, a chromogenic β-lactam, as a substrate and observed that hydrolytic activity of Ldt Mav2 peaks in the physiological pH range (Figure 2A) . Ldt Mav2 displayed a classical Michaelis-Menten kinetics for hydrolysis of nitrocefin with K m and V max of 75 μM and 6.5 μM/min, respectively. Additionally the kinetic parameters with respect to hydrolysis of nitrocefin are comparable to Ldt Mt2 [30] and Ldt Mt5 [20] . (Figure 2B ).
• Carbapenems & cephalothin irreversibly inhibit Ldt Mav2
Although β-lactams bind to and inhibit D,Dtranspeptidases [35] , it is not known if this antibacterial class interacts with Ldt Mav2 . We studied the nature of the reaction between Ldt Mav2 and different β-lactam subclasses using UPLC-MS. Amoxicillin and ampicillin were used as representatives of penicillin subclass; cephalothin and cefoxitin are cephalospirins; and doripenem, biapenem and tebipenem are carbapenems while faropenem is a penem. While cephalothin, imipenem, doripenem, biapenem, faropenem and tebipenem formed covalent acyl-adducts, we were unable to detect any reacted masses for amoxicillin, ampicillin, cefoxitin and meropenem (Table 1) . Additionally, we used nitrocefin as a substrate to monitor Ldt Mav2 activity following treatment with the β-lactams. Hydrolysis of nitrocefin by Ldt Mav2 was significantly inhibited when the enzyme was treated with faropenem or tebipenem ( Figure 2C ). Cefoxitin, amoxicillin and ampicillin failed to inhibit the enzyme as nitrocefin hydrolysis occurred despite treatment with these agents.
• Kinetics of acylation of Ldt Mav2
Kinetics of Ldt Mav2 acylation by various β-lactams was assessed in the presence of MIC 90 of various drugs in μg/ml determined using two growth broths/pH as per Clinical and Laboratory Standard Guidelines [26] . T210 is a synthetic carbapenem [10] . We assessed a panel of β-lactams, including newer carbapenems, for activity against M. avium according to CLSI guidelines [26] . Tebipenem, a recently developed carbapenem with oral bioavailability and potency against M. tuberculosis [33] , exhibited MIC 90 of 2-4 μg/ml at pH 6.8 and 4-8 μg/ml in the pH 7.4 and was the only β-lactam (among those tested in this study) with a potency in the therapeutically relevant range. Other carbapenems failed to inhibit M. avium growth even at 64 μg/ml, the highest concentration in the range tested (Table 2) . Next, we supplemented each of these β-lactams with clavulanate, 5 μg/ml, to assess if this β-lactamase inhibitor enhanced the susceptibility of M. avium to the β-lactams: the MIC of the β-lactams were not altered by the addition of clavulanate.
Incubation of Ldt Mav2 with tebipenem (Molecular weight; MW = 383.5 Da) produced a covalently bound acyl adduct of +339 Da (Table 1 ). The catalytic domain of Ldt Mt2 and the homologous domain in Ldt Mav2 share 96% sequence identity (Supplementary Figure 1) and Cys 354 are involved in coordination and reaction with carbapenems [36] . These residues are conserved in Ldt Mav2 . Based on these data, we propose the following mechanism for tebipenem adduct formation with Ldt Mav2 . Sulfur atom of the putative catalytic Cys 349 makes a nucleophilic attack to the carbonyl carbon of β-lactam ring and opens the ring ( Figure 4A) . Next, as in meropenem and tebipenem reactions with Ldt Mt2 [36] , hydroxyethyl group at C6 is lost resulting in an adduct of +339 Da.
Carbapenems and rifampin exhibit synergy in vitro against M. tuberculosis and M. abscessus [27] . We hypothesized that tebipenem may exhibit synergy with rifampin against M. avium. Checker board assay revealed a lack of synergy between tebipenem and rifampin against this mycobacterium (Supplementary Table 1 ). Clarithromycin and moxifloxacin are commonly used for treatment of M. avium infections [37] . We also studied potencies of combination of clarithromycin or moxifloxacin and tebipenem; these combinations failed to exhibit synergy against M. avium Table 1 ).
• Molecular modeling of Ldt Mav2 with putative substrate
Structural characterization of Ldt Mav2 can provide further insight into its biochemical properties. Using the crystal structure of Ldt Mt2 with a native peptide substrate bound to its catalytic site (PDB ID: 3TUR) [30] as a template, we used homology modeling to generate a 3D model of Ldt Mav2 ( Figure 4B) (Figure 4C ) reveals that residues involved in substrate binding are conserved in the two proteins, suggesting a similar mechanism of catalysis and substrate specificities.
Discussion
Mycobacterial genomes encode multiple sequence orthologs with the YkuD domain (Figure 1) . The presence of this domain is predictive of a function related to L,Dtranspeptidation. While a recent study ascribed L,D-transpeptidase function to the paralogs in M. tuberculosis using an in vitro peptide cross-linking assay [38] , studies that evaluated strains lacking each paralog concluded them future science group www.futuremedicine.com to be functionally nonredundant [6, 14, 20] . The presence of six sequence orthologs in M. avium genome illustrates that a significant catalytic potential of this protein class is preserved by this pathogen and perhaps also suggests their importance to this organism. In this study, we have chosen to characterize Ldt Mav2 , whose ortholog in M. tuberculosis (Ldt Mt2 ) is the dominant L,D-transpeptidase [6] .
As β-lactams are known to mimic peptide substrates of peptidoglycan biosynthesis [35] and Ldt Mav2 readily hydrolyzed nitrocefin, a β-lactam, it is reasonable to expect that this enzyme uses peptides or related biomolecule as its native substrate. Localization of Ldt Mav2 in the cell wall further suggests that similar to its ortholog Ldt Mt2 , it is likely anchored to the cell membrane with a single transmembrane domain and catalyzes formation of 3→3 linkages in the peptidoglycan layer. We found that Ldt Mav2 associates with a putative Ser/Thr kinase (accession #: 48928156) possessing a homodimer interface for peptide-binding site. These two proteins exist at the site of peptidoglycan synthesis. Therefore, it is possible that the homodimer interface interacts with the stem peptide fragments generated and released during peptidoglycan metabolism and the Ser/ Thr kinase domain of the protein transmits this signal to Ldt Mav2 or another protein. There is a precedent to this mechanism: in Bacillus subtilis a conserved membrane bound Ser/Thr kinase binds to peptidoglycan fragments and regulates spore germination [39] . The presence of similar levels of Ldt Mav2 during exponential and stationary phases of growth suggests that activity conferred by this protein is likely required constitutively by M. avium. Lower abundance of the protein, especially when M. avium is exposed to osmotic shock or tebipenem, suggests that this organism may also deploy alternative mechanisms to fortify its cell wall.
Treatment of infections with drug-resistant strains of M. avium pose serious challenges as the limited choices of antibacterials are often not well tolerated by patients. Therefore, availability of new and well-tolerated treatment agent that functions by inhibiting previously unexploited target can have a direct impact on the health of patients with M. avium infection. Consistent with the recent observations that M. tuberculosis L,D-transpeptidases are irreversibly inhibited by carbapenems [36, 38] , we also observed that stable covalent adducts are formed between Ldt Mav2 and carbapenems. The efficiency of acylation of Ldt Mav2 , as can be described by k inact /K app , shows similar acylation kinetics among the carbapenems. However, this in vitro inhibition did not completely predict whole-cell activity: although all tested carbapenems except meropenem covalently acylated Ldt Mav2 , only tebipenem exhibited whole-cell potency against M. avium. Several possibilities can be speculated to account for the apparent difference between in vitro and whole-cell activities. We hypothesize that tebipenem may be uniquely resistant to hydrolytic activity of the native β-lactamase in M. avium. Equally likely is that tebipenem selectively inhibits other transpeptidases in addition to Ldt Mav2 . The most interesting observation with immediate clinical relevance is that tebipenem not only inhibits Ldt Mav2 but is also highly potent against M. avium. Therefore, this orally bioavailable antibacterial, from a class namely carbapenems that are generally well tolerated, has the potential to be repurposed as a much needed new therapy to treat M. avium infections. Studies herein, however, do not directly prove if inhibition of Ldt Mav2 by tebipenem is sufficient to dictate susceptibility of M. avium to this carbapenem.
Conclusion
M. avium genome also encodes for nonclassical transpeptidases, namely L,D-transpeptidases that generate unique 3→3 cross-linkages in the peptidoglycan layer. Tebipenem, a new orally bioavailable carbapenem, not only inhibits M. avium L,D-transpeptidase but also potently inhibits the growth of this pathogen, thereby raises the possibility of using this potent antibiotic to treat conditions arising from infection with this organism. 
Future perspective
Financial & competing interests disclosure
